Hopstem’s neural progenitor cell injection earns FDA RMAT designation for chronic stroke

Edited by Robert McTiernan··2 min read

Houston-based Hopstem Biotechnology announced receipt of a Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA for hNPC01, an iPSC-derived human forebrain neural progenitor cell injection, for the treatment of persistent motor dysfunction resulting from basal ganglia ischemic stroke. The designation — which the company states is the first RMAT award globally for any therapy targeting chronic motor impairment from stroke — builds on a prior FDA Fast Track designation for the same program.

RMAT designation, established under the 21st Century Cures Act, incorporates all Fast Track benefits and adds intensive early FDA interaction, rolling review eligibility, and potential access to accelerated approval pathways. Hopstem stated the FDA will convene a dedicated comprehensive consultation meeting to help shape the Phase II/III clinical development plan and commercial manufacturing strategy for hNPC01.

hNPC01 is delivered by direct injection and is designed to differentiate into functional forebrain neurons in vivo, integrate into multi-region brain neural circuits, and reconstitute damaged endogenous networks — a cellular engraftment approach distinct from receptor-targeted pharmacological agents. Preclinical data published in Nature Communications support this mechanism, demonstrating in vivo neuronal differentiation and circuit integration, though specific quantitative outcomes from those studies were not disclosed in the company’s announcement.

The AllSci BriefSystematic R&D and deal news. Daily.

The clinical foundation for the RMAT award is a China-based Phase I study enrolling 23 patients with chronic ischemic stroke, defined as stroke onset between six months and five years prior to enrollment, with persistent hemiplegia affecting the basal ganglia. According to a January 2026 company announcement — the most detailed public source available — 12-month follow-up data from that cohort indicated clinical improvement in stroke-induced hemiplegia and a manageable safety profile. Neither specific efficacy metrics such as Fugl-Meyer Assessment score changes or modified Rankin Scale shifts, nor p-values, have been disclosed in any publicly available source to date. The most data-rich public presentation identified was a late-breaking poster at the May 2024 American Society of Gene and Cell Therapy annual meeting, but full numeric content from that poster is not publicly retrievable.

Those Phase I results were sufficient for the FDA to authorize progression to a Phase II/III adaptive pivotal trial with a bridging study, as noted in the January 2026 release — the same data package that underpins the current RMAT award.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/